Influence of Empagliflozin combination therapy on cardiac function,renal function and prognosis in elderly patients with type 2 diabetes mellitus complicated with acute heart failure
WU Jiahong
WANG Tao
ZHANG Youtao
WANG Hong
YANG Xiaomin
ZHANG Qian
DONG Liping
Abstract：Objective To investigate the effects of Empagliflozin combination therapy on cardiac function,renal function and prognosis in elderly patients with type 2 diabetes mellitus(T2DM)complicated with acute heart failure(AHF).Methods A total of 160 patients with T2DM and AHF admitted from January to July 2023 were selected as the research subjects and divided into the observation group(n=80)and the control group(n=80)by the random number table method.The control group was given conventional hypoglycemic and anti-AHF treatment,while the observation group was supplemented with Empagliflozin on the basis of the control group.Both groups were treated continuously for 6 months.The cardiac function indicators of the two groups before and after treatment[left ventricular ejection fraction(LVEF),6-minute walking distance(6MWD),N-terminal pro-brain natriuretic peptide(NT-proBNP),renal function parameters[blood urea nitrogen(BUN),urinary albumin-to-creatinine ratio(UACR),estimated glomerular filtration rate(eGFR)],blood glucose control status[fasting blood glucose(FBG),2-hour postprandial blood glucose(2 h PBG),glycated hemoglobin(HbA1c)]before and after treatment were compared between the two groups,and the treatment safety of the two groups was evaluated.The patients were followed up for one year.The occurrence of major adverse cardiovascular events(MACE)and the scores of the World Health Organization Quality of Life Scale(QQL-100)at 1,3,6 and 12 months after treatment were recorded in both groups.Results After treatment,the LVEF and 6MWD in both groups were higher than those before treatment,notably in the observation group(P<0.05,P<0.01),while the NT-proBNP in both groups was lower after treatment than that before treatment,notably in the observation group(P<0.05,P<0.01).After treatment,the eGFR in the observation group was higher than that before treatment,and also higher in the observation group than in the control group(P<0.05,P<0.01).After treatment,BUN and UACR in the observation group were lower than those before treatment,and lower in the observation group than in the control group(P<0.05,P<0.01).After treatment,FBG,2 h PBG and HbA1c in both groups were lower than those before treatment,and even lower in the observation group(P<0.05,P<0.01).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The total incidence of MACE in the observation group was lower than that in the control group at 1-year follow-up(P<0.05),while the QL-100 scores of the observation group at 1,3,6 and 12 months after treatment were all higher than those of the control group(P<0.05).Conclusion Empagliflozin combination therapy can effectively ameliorate cardiac function,renal function and blood glucose level in elderly patients with T2DM and AHF,reduce the incidence of MACE,improve the quality of life,and has good safety.
Keywords：type 2 diabetesacute heart failureelderlyEmpagliflozinleft ventricular ejection fractionestimated glomerular filtration ratefasting blood glucosemajor adverse cardiovascular events
Publication Date：2025-12-13
Online Publishing Date：2025-12-25(First online date of this platform, not the publication date of the document)
Pages：7( 31-37 )